South Bay Lawmaker Criticizes Trump Admin’s Hepatitis B Study

WASHINGTON, December 25, 2025 00:33:00 – A federal research study examining the potential impact of rolling back the birth dose of the hepatitis B vaccine is facing scrutiny, with critics alleging it was designed to justify a policy already put in place. The controversy centers on whether the study is a genuine attempt to assess broader health effects or a preordained effort to provide cover for a policy shift.

Concerns Raised Over Study’s Origins and Rigor

A House Science Committee inquiry revealed the research wasn’t initiated through a standard competitive grant process. Instead, the committee found that officials specifically sought out researchers for the study, raising questions about it’s objectivity and potential for bias. Experts are also warning the study may lack the statistical rigor needed to draw meaningful conclusions about long-term health impacts.

• A House Science Committee investigation revealed the research wasn’t initiated through a standard competitive grant process.
• Experts warn the study may lack the statistical rigor needed to draw meaningful conclusions about long-term health impacts.
• Critics estimate a rollback of the birth dose could lead to hundreds of additional infections and preventable deaths annually.

Could eliminating the birth dose of the hepatitis B vaccine lead to a resurgence of the disease? The potential consequences of altering the current vaccination schedule are sparking debate, with some experts predicting a important increase in infections and fatalities. Scott estimated that if the birth dose is successfully rolled back on a larger scale, it could lead to 1,400 additional chronic pediatric infections and nearly 500 preventable deaths annually. “They’re doing that to generate evidence for a policy they have already implemented,” Scott said. “It’s clearly going to cause far more harm then any benefits.” According to background data from the House Science Committee staff, the research group did not apply for an award through a standard competitive process; instead, staff said Kennedy specifically sought out the researchers. This raises questions about the objectivity of the study and whether it was designed to achieve a predetermined outcome.

The typical process for funding research involves a request for proposals, allowing for a rigorous evaluation of potential studies. In this case, that standard procedure was bypassed, raising concerns about the study’s scientific integrity.

Arthur reingold, a former professor of epidemiology at UC Berkeley and a former Chief of the Respiratory Diseases Branch at the CDC, emphasized the importance of a robust study protocol. “The typical way of going about it is to put out a request for proposal … and fund the most rigorous study,” Reingold said. “Obviously, that was not done in this case.” He added that without a detailed protocol, it’s impossible to determine if the trial can accurately measure the “broader health effects” the Department of Health and Human Services (HHS) claims to be investigating. Reingold warned that a study lacking sufficient statistical power is simply a “waste of money.” The House Science Committee stated it is indeed considering all oversight options, though staff noted their authority is currently limited by their status in the Minority. This suggests a potential for further investigation as the committee seeks to understand the circumstances surrounding the study and its implications for public health policy.

The debate over the hepatitis B vaccine highlights the complex interplay between scientific research, policy decisions, and public health.Ensuring the integrity of research and transparency in policy-making are crucial for maintaining public trust and protecting the health of the population.